FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. FLT3 is the receptor for the cytokine Flt3 ligand (FLT3L). FLT-3 is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). Besides, high levels of wild-type FLT3 have been reported for blast cells of some AML patients without FLT3 mutations. These high levels may be associated with worse prognosis. Signaling through FLT3 plays a role in cell survival, proliferation, and differentiation. FLT3 is important for lymphocyte (B cell and T cell) development, but not for the development of other blood cells. Two cytokines that down modulate FLT3 activity are TNF-Alpha and TGF-Beta.
### FLT3 Inhibitors & Modulators

**AC710**  
**Cat. No.: HY-13493**  
**Bioactivity:** AC710 is a potent PDGFR inhibitor with $K_i$ of 0.6, 1.57, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRa and PDGFR$\beta$, respectively.  
**Purity:** 99.03%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**AMG 925**  
**Cat. No.: HY-15889**  
**Bioactivity:** AMG 925 is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with $IC_{50}$ of 2±1 nM and 3±1 nM, respectively.  
**Purity:** 99.33%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

**AST 487**  
**Cat. No.: HY-15002**  
**Bioactivity:** AST 487 is a RET kinase inhibitor with $IC_{50}$ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with $IC_{50}$ of 520 nM.  
**Purity:** 98.64%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

**BPR1J-097**  
**Cat. No.: HY-13537**  
**Bioactivity:** BPR1J-097 is a novel potent FLT3 inhibitor with an $IC_{50}$ of 11nM.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

**BSc5371**  
**Cat. No.: HY-111545**  
**Bioactivity:** BSc5371 is a potent and irreversible FLT3 inhibitor, with $K_i$ of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. BSc5371 is cytotoxic...  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 500 mg, 100 mg, 250 mg

**Altiratinib**  
**(DCC-2701)**  
**Cat. No.: HY-B0791**  
**Bioactivity:** Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with $IC_{50}$s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.  
**Purity:** 95.95%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**AMG 925 HCl**  
**Cat. No.: HY-15889A**  
**Bioactivity:** AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with $IC_{50}$ of 2±1 nM and 3±1 nM, respectively.  
**Purity:** 98.91%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

**AZD2932**  
**Cat. No.: HY-18179**  
**Bioactivity:** AZD2932 is a potent and multi-targeted kinase inhibitor, $IC_{50}$s of 8, 4, 7 and 9 nM in cell assay, respectively.  
**Purity:** 98.12%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**BPR1J-097 Hydrochloride**  
**Cat. No.: HY-13537A**  
**Bioactivity:** BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an $IC_{50}$ of 11nM.  
**Purity:** 98.01%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**BSc5371**  
**Cat. No.: HY-13016**  
**Bioactivity:** Cabozantinib is a potent multiple receptor tyrosine kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with $IC_{50}$s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.  
**Purity:** 99.92%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

**Tel:** 609-228-6898  
**Fax:** 609-228-5909  
**Email:** sales@MedChemExpress.com
<table>
<thead>
<tr>
<th><strong>CCT241736</strong></th>
<th><strong>Cat. No.: HY-18161</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A $K_d$ 7.5 nM, $IC_{50}$ 38 nM; Aurora-B $K_d$ 6.8 nM), FLT3 kinase ($K_d$ 6.2 nM), and FLT3 mutants includ...</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CG-806</strong></th>
<th><strong>Cat. No.: HY-112646</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>CG-806 is a pan FLT3/BTK Multi-Kinase inhibitor.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CHIR-124</strong></th>
<th><strong>Cat. No.: HY-13263</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>CHIR-124 is a potent and selective Chk1 inhibitor with $IC_{50}$ of 0.3 nM, and also potently targets PDGFR and FLT3 with $IC_{50}$ of 6.6 nM and 5.8 nM.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **Dovitinib**  
(CHIR-258, TKI258) | **Cat. No.: HY-50905** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Dovitinib is a multi-targeted tyrosine kinase inhibitor with $IC_{50}$ of 1.2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRa/β, respectively.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.31%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 3</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 200 mg, 500 mg</td>
</tr>
</tbody>
</table>

| **ENMD-2076**  
CAT. NO.: HY-10987A | **Bioactivity:** | ENMD-2076 is a multi-targeted kinase inhibitor with $IC_{50}$ of 1.86, 14, 5.82, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRa, respectively. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity:</strong></td>
<td>99.23%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **ENMD-2076 Tartrate**  
Cat. No.: HY-10987 | **Bioactivity:** | ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with $IC_{50}$ of 1.86, 14, 5.82, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRa, respectively. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity:</strong></td>
<td>98.59%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **FLT3-IN-1**  
Cat. No.: HY-109584 | **Bioactivity:** | FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **FLT3-IN-1 Succinate**  
Cat. No.: HY-109584A | **Bioactivity:** | FLT3-IN-1 Succinate is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **FLT3-IN-2**  
Cat. No.: HY-18744 | **Bioactivity:** | FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3-IN-3</td>
<td>HY-112145</td>
<td>FLT3-IN-3 is a potent FLT3 inhibitor with IC$_{50}$ of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>100 mg, 500 mg, 250 mg</td>
</tr>
<tr>
<td>FLT3-IN-4</td>
<td>HY-128571</td>
<td>FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC$_{50}$=7 nM) inhibitor for treating acute myelogenous leukemia [1].</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>500 mg, 100 mg, 250 mg</td>
</tr>
<tr>
<td>FLT3-IN-6</td>
<td>HY-128572</td>
<td>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC$_{50}$ of 1.336 nM [1].</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>250 mg, 500 mg, 100 mg</td>
</tr>
<tr>
<td>FN-1501</td>
<td>HY-111361</td>
<td>FN-1501 is a potent inhibitor of FLT3 and CDK, with IC$_{50}$ of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.</td>
<td>98.41%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>G-749</td>
<td>HY-12333</td>
<td>G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC$_{50}$s of 0.06/0.6/3.9/7.5 nM for WI Flt3/DB35Y/MV4-11/Molm-14 respectively.</td>
<td>99.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
<tr>
<td>Gandotinib</td>
<td>HY-13034</td>
<td>Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC$<em>{50}$ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC$</em>{50}$ of 4, 25, 32, 44, and 95 nM.</td>
<td>99.96%</td>
<td>Phase 2</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Gilteritinib</td>
<td>HY-12432</td>
<td>Gilteritinib is a potent FLT3/ AXL inhibitor with IC$_{50}$ of 0.29 nM/0.73 nM, respectively.</td>
<td>99.55%</td>
<td>Phase 3</td>
<td>5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Gilteritinib</td>
<td>HY-12432A</td>
<td>Gilteritinib hemifumarate is a potent FLT3/ AXL inhibitor with IC$_{50}$ of 0.29 nM/0.73 nM, respectively.</td>
<td>99.22%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>JNJ-47117096</td>
<td>HY-12420</td>
<td>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC$<em>{50}$ of 23 nM, also effectively inhibits Flit3, with an IC$</em>{50}$ of 18 nM.</td>
<td>99.40%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>KW-2449</td>
<td>HY-10339</td>
<td>KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL$^{{T315I}}$, and Aurora kinase with IC$_{50}$ of 6.6, 14, 4 and 48 nM, respectively.</td>
<td>99.85%</td>
<td>Phase 1</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>
**Lestaurtinib**
(CEP-701; KT-5555)  
Cat. No.: HY-50867

**Bioactivity:** Lestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3 and TrkA with IC₅₀ values of 0.5, 3 and less than 25 nM, respectively.

**Purity:** 99.92%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg

---

**Linifanib**
(ABT-869; AL-39324)  
Cat. No.: HY-50751

**Bioactivity:** Linifanib (ABT-869) is a multi-targeted inhibitor of VEGF and PDGFR receptor family with IC₅₀ values of 3, 4, 66, 4 nM for KDR, Flt-1, PDGFRβ and FLT3, respectively.

**Purity:** 99.60%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

---

**MRX-2843**
(UNC2371)  
Cat. No.: HY-101549

**Bioactivity:** MRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3.

**Purity:** 99.21%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

---

**Pacritinib**
(SB1518)  
Cat. No.: HY-16379

**Bioactivity:** Pacritinib is a potent inhibitor of both wild-type JAK2 (IC₅₀ = 23 nM) and JAK2V617F mutant (IC₅₀ = 19 nM). Pacritinib also inhibits FLT3 (IC₅₀ = 22 nM) and its mutant FLT3D835Y (IC₅₀ = 6 nM).

**Purity:** 99.66%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Quizartinib**
(AC220)  
Cat. No.: HY-13001

**Bioactivity:** Quizartinib (AC220) is a potent Flt3 tyrosine kinase inhibitor with a Kᵝ of 1.6±0.7 nM.

**Purity:** 99.34%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

---

**Rebastinib**
(DCC-2036)  
Cat. No.: HY-13024

**Bioactivity:** Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC₅₀ values of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.

**Purity:** 99.91%

**Clinical Data:** Phase 1

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

---

**SB1317**
(TG02)  
Cat. No.: HY-15166

**Bioactivity:** SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 for the treatment of cancer, with IC₅₀ values of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.

**Purity:** 99.96%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Sitravatinib**
(MGCD516; MG516)  
Cat. No.: HY-16961

**Bioactivity:** Sitravatinib (MGCD516; MG516) is an orally bioavailable, inhibitor with IC₅₀ values of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DD...

**Purity:** 99.85%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

**SKLB4771**
FLT3-IN-1)  
Cat. No.: HY-12960

**Bioactivity:** SKLB4771 is a novel potent and selective Flt3 inhibitor with IC₅₀ of 10 nM against FLT3-ITD-expressing MV4-11 cells with IC₅₀ of 6 nM. IC50 value: 10 nM (in vitro) [1] Target: in vitro: SKLB4771 inhibited FLT3 phosphorylation in a dose-dependent manner. Consistent with the downregulation of...

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Sorafenib**
(Bay 43-9006)  
Cat. No.: HY-10201

**Bioactivity:** Sorafenib (Bay 43-9006) is a potent multikinase inhibitor with IC₅₀ values of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

**Purity:** 99.92%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg
| **Sorafenib Tosylate**  
*(Bay 43-9006 (Tosylate))* | **Cat. No.: HY-10201A** | **Bioactivity:** | Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent multikinase inhibitor, with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.  
Purity: 99.33%  
Clinical Data: No Development Reported  
Size: 10mM x 1mL in DMSO, 100 mg, 500 mg |
|---|---|---|---|
| **Tandutinib**  
*(MLN518; CT53518)* | **Cat. No.: HY-10202** | **Bioactivity:** | Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. IC50 value: 0.22 μM [1] Target: Flt3; PDGFRβ; c-Kit in vitro...  
Purity: 98.81%  
Clinical Data: Phase 2  
Size: 10mM x 1mL in DMSO, 50 mg, 100 mg |
| **TCS 359** | **Cat. No.: HY-13907** | **Bioactivity:** | TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent inhibitor of FLT3 with IC50 of 42 nM.  
Purity: 99.51%  
Clinical Data: No Development Reported  
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg |
| **TG101209** | **Cat. No.: HY-10410** | **Bioactivity:** | TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.  
Purity: 98.94%  
Clinical Data: No Development Reported  
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |
| **UNC2025** | **Cat. No.: HY-12344** | **Bioactivity:** | UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3. IC50 value: 0.8/0.74 nM(MER/FLT3) Target: Mer/Flt3 inhibitor UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies...  
Purity: 99.97%  
Clinical Data: No Development Reported  
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |
| **UNC2025 hydrochloride** | **Cat. No.: HY-12344A** | **Bioactivity:** | UNC2025 hydrochloride is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3. IC50 value: 0.8/0.74 nM (MER/FLT3) Target: Mer/Flt3 inhibitor UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD)...  
Purity: 99.83%  
Clinical Data: No Development Reported  
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |